Skip to main content
Livermore
Livermore
ZHEN

BIOS Capital Management, LP

SEC CIK
0001813845
Latest filing
Aug 14, 2026

The latest 13F from BIOS Capital Management, LP covers Q2 2026 (filed Aug 14, 2026): 6 long positions worth $41.7M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Actuate Therapeutics, Inc. (ACTU) at 36.9%. Livermore has 8 filings on Form 13F from this institution, going back to Q4 2024.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
1
Est. +$1.04M
Reduced
2
Est. −$2.69M
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. ACTUActuate Therapeutics, Inc.
    36.9%$15.4MHistory
  2. IRDOpus Genetics, Inc.
    36.3%$15.1MHistory
  3. CGTXCognition Therapeutics Inc
    16.6%$6.90MHistory
  4. RNTXRein Therapeutics, Inc.
    7.4%$3.10MHistory
  5. LTRNLantern Pharma Inc.
    2.5%$1.04MHistory

Share of portfolio

Top 5 holdings and the other 1 position, by share of portfolio value

  1. ACTU36.9%
  2. IRD36.3%
  3. CGTX16.6%
  4. RNTX7.4%
  5. LTRN2.5%
  6. Other 1 position0.3%

Biggest buys

New and added positions, by estimated amount bought

  1. RNTXRein Therapeutics, Inc.
    +$1.04MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. RNTXRein Therapeutics, Inc.
    +2.57 pp4.9% → 7.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. LTRNLantern Pharma Inc.
    −$2.56MReducedHistory
  2. INABIN8BIO, Inc.
    −$122.5KReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. INABIN8BIO, Inc.
    −0.20 pp0.5% → 0.3%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$41.7M
−$11.2M (−21.2%) vs. prior quarter
Positions
6
0 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
2.2%
Q2 2026, one quarter
Average holding period
7.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2024), so positions held before then are understated.

13F filings by quarter

7 quarters, going back to Q4 2024. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $94.1M (Q4 2024)

Q4 2024: $94.1MQ1 2025: $79.2MQ2 2025: $72.6MQ3 2025: $88.9MQ4 2025: $82.6MQ1 2026: $52.9MQ2 2026: $41.7M
Q4 2024Q2 2026
13F filings of BIOS Capital Management, LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20266$41.7MACTUIRDCGTXvs. Q1 2026SEC
Q1 2026May 13, 20266$52.9MACTUIRDCGTXvs. Q4 2025SEC
Q4 2025Feb 13, 20266$82.6MACTUCGTXIRDvs. Q3 2025SEC
Q3 2025Nov 12, 20256$88.9MACTUCGTXIRDvs. Q2 2025SEC
Q2 2025Aug 12, 20256$72.6MACTUIRDLTRNvs. Q1 2025SEC
Q1 2025May 14, 20256$79.2MACTULTRNRNTXvs. Q4 2024SEC
Q4 2024Feb 18, 2025Amended6$94.1MACTUCGTXRNTX–SEC

13D and 13G filings

Companies where BIOS Capital Management, LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

BIOS Capital Management, LP does not currently report owning 5% or more of any company.

Latest filings

12 filings on file made by BIOS Capital Management, LP or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by BIOS Capital Management, LP
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
LTRNLantern Pharma Inc.May 15, 20264:20 PM ETBios Equity Partners, LPand 13 others13D/A4.48%571.3K shares−2.92 ppfrom 7.40%Below 5%May 15, 2026SEC
IRDOpus Genetics, Inc.May 13, 202611:07 AM ETBIOS Fund III, LPand 9 others13G/A4.53%3.68M shares−1.67 ppfrom 6.20%Below 5%May 12, 2026SEC
RNTXRein Therapeutics, Inc.May 8, 202611:33 AM ETBIOS Fund I, LPand 23 others13G/A9.99%7.80M shares–May 6, 2026SEC
LTRNLantern Pharma Inc.Apr 16, 20263:48 PM ETBios Equity Partners, LPand 13 others13D/A7.40%834.8K shares−1.18 ppfrom 8.58%Apr 16, 2026SEC
LTRNLantern Pharma Inc.Feb 23, 20264:37 PM ETBios Equity Partners, LPand 13 others13D/A8.58%960.0K shares−1.40 ppfrom 9.98%Feb 20, 2026SEC
INABIN8BIO, Inc.Dec 29, 20254:00 PM ETBIOS Fund II, LPand 18 others13D/A4.00%391.4K shares−5.99 ppfrom 9.99%Below 5%Dec 22, 2025SEC
CGTXCognition Therapeutics IncSep 23, 20259:58 PM ETBIOS Memory SPV I, LPand 21 others13D/A6.90%6.06M shares–Sep 19, 2025SEC
IRDOpus Genetics, Inc.Aug 11, 20256:56 PM ETBIOS Fund III, LPand 9 others13G6.20%3.68M sharesNewMay 5, 2025SEC
ACTUActuate Therapeutics, Inc.Jun 30, 202512:08 PM ETBIOS Fund I, LPand 23 others13D/A49.80%10.3M shares−2.60 ppfrom 52.40%Jun 27, 2025SEC
LTRNLantern Pharma Inc.Jun 13, 20257:43 PM ETBios Equity Partners, LPand 13 others13D/A9.98%1.08M shares–Jun 12, 2025SEC
ACTUActuate Therapeutics, Inc.May 27, 20254:15 PM ETBIOS Fund I, LPand 23 others13D/A52.40%10.0M shares–May 22, 2025SEC
INABIN8BIO, Inc.May 8, 20255:53 PM ETBIOS Fund II, LPand 18 others13D/A9.99%9.12M shares–May 2, 2025SEC